BRAF and metastatic melanoma: The National Comprehensive Cancer Network (NCCN) as well as the American Society of Clinical Oncology recommend genetic testing for patients with unresectable or metastatic melanoma to guide treatment, especially if patients are found to be BRAF mutation carriers [8-9].